Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 2, 2011, Pages 359-369

  Douglas, Jason B ^a   Silverman, Debra T ^a   Weinstein, Stephanie J ^a   Graubard, Barry I ^a   Pollak, Michael N ^b   Tao, Yuzhen ^b   Virtamo, Jarmo ^c   Albanes, Demetrius ^a   Stolzenberg Solomon, Rachael Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEDENTARY LIFESTYLE; SMOKING; UNEMPLOYMENT;

ADENOCARCINOMA; AGED; ALPHA-TOCOPHEROL; BETA CAROTENE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVENTION STUDIES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PLACEBOS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; VITAMINS;

EID: 79951592481     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-1024     Document Type: Article

References (31)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7. (Pubitemid 36019639)
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
3. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-90. (Pubitemid 38500312)
4. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2009;35:605-10.
5. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
6. Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002;136:529-33.
7. Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 2010;10:203. [Epub ahead of print]
8. Miyake K, Imura S, Nishioka M, Batmunkh E, Sugimoto K, Ohmoto Y, et al. Serum evaluation of soluble interferon-α/β receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine 2010; 49:251-5.
9. Mahmoud FA, Rivera N. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-5.
10. Ognjanovic S, Yamamoto J, Saltzman B, et al. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control 2010;21:1131-8.
11. Zhang SM, Buring JE, Lee I, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Med 2005;142:425-32.
12. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66:2483-7.
13. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-4. (Pubitemid 43348407)
14. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, et al. Systematic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21-3. (Pubitemid 40188430)
15. Tingstedt B, Johansson P, Andersson B, Andersson R. Predictive factors in pancreatic ductal adenocarcinoma: role of inflammatory response. Scand J Gastroenterol 2007;42:754-9. (Pubitemid 46763583)
16. ATBC Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994; 4:1-10.
17. Pietinen P, Hartman AM, Haapa E, Rasanen L, Haapakoski J, Palmgren J, et al. Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. Am J Epidemiol 1988;128:655-666.
18. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21:273S-309S.
19. Thompson FE, Kipnis V, Midthune D, Freedman LS, Carroll RJ, Subar AF, et al. Performance of a food-frequency questionnaire in the US NIH-AARP (National Institutes of Health-American Association of Retired Persons) Diet and Health Study. Public Health Nutr 2008; 11:183-95.
20. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006;66:10213-19. (Pubitemid 44672077)
21. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, et al. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers.Am J Epidemiol 2008;168: 1047-55.
22. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Res 2009;69:1439-47.
23. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 2002;41:381-388.
24. Fears TR, Ziegler RG, Donaldson JL, Falk RT, Hoover RN, Stanczyk FZ, et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev 2000;9:403-12. (Pubitemid 30265784)
25. De Onis M, Habicht JP. Anthropometric reference data for international use: recommendations from a World Health Organization Expert Committee. Am J Clin Nutr 1996;650-8.
26. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 1986;124:17-27. (Pubitemid 16095831)
27. Anderson KE, Mack TM, Silverman DT. Cancer of the pancreas. In: Schottenfeld D, Fraumeni JF Jr., editors. Cancer epidemiology and prevention. New York: Oxford University Press; 2006. p. 721-62.
28. Du Clos TW. Function of C-reactive protein. Ann Med 2000;32:274-8. (Pubitemid 30311864)
29. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains and anti-inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-64.
30. Van Der Vaart H, Postma DS, Timens W, Hylkema MN, Willemse BW, Boezen HM, et al. Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res 2005;6:1-11.
31. Chung HY, Kim HJ, Kim JW, Yu BP. The inflammation hypothesis and aging. Ann N Y Acad Sci 2006;928:327-35.